// App-Quantinova.ai

: Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the open-label extension period of the BE RADIANT phase 3b trial

Researchers

Presenter

  • Bruce Strober

Principal Investigators

  • Carle Paul

  • Andrew Blauvelt

  • Diamant Thaçi

  • Boni Elewski

  • Katy White

  • Veerle Vanvoorden

  • Delphine Deherder

  • Fabienne Staelens

  • Kilian Eyerich

Medical Centers

  • Yale University, New Haven, CT

  • Central Connecticut Dermatology, Cromwell, CT, USA

  • Toulouse University and CHU, Toulouse, France

  • Oregon Medical Research Center, Portland, OR, USA, Portland, OR

  • Comprehensive Center for Inflammation Medicine, University of Lubeck, Lubeck, Germany

  • Department of Dermatology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH, USA

  • UCB Pharma, Slough

  • UCB Pharma, Brussels, Belgium

  • UCB Pharma, Braine-l’Alleud, Belgium

  • Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany

Locations

  • Germany

  • Belgium

  • United States

  • France

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • bimekizumab

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

  • Open Label

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved